Features Screener Stocks Charts
Sign In Sign Up

Jyothy Laboratories Limited Fundamental Analysis Revenue, Profits & Valuation

NSE: JYOTHYLAB | BSE: 532926 | PERSONAL CARE
Price ₹199.98 ₹0.01 (-0.01%)
P/E Ratio 19.8 TTM
52-Week Range
Low ₹196 High ₹365
Market Cap ₹73.40B Billion
ROE 18.1% Annual

Market data as of Jun 3, 2026

How has Jyothy Laboratories Limited (JYOTHYLAB) been performing? We dig into revenue, profitability, valuation, and ownership trends.

Jyothy Lab Revenue Trend

Top-line growth continued for Jyothy Laboratories Limited, with FY2025 revenue reaching ₹2,903 Cr — a 3.3% increase over FY2024.

Looking at the longer trend, Jyothy Laboratories Limited's revenue grew from ₹1,515 Cr to ₹2,903 Cr at a 6.7% CAGR — moderate, consistent growth.

With a top line of ₹2,903 Cr, Jyothy Laboratories Limited operates at a mid-sized scale within the personal care sector.

Jyothy Laboratories Limited has posted revenue growth for 5 consecutive years — that's a sustained trend, not a one-off.

Revenue Trend
YearRevenueYoY %
FY2025₹2,903 Cr+3.3%
FY2024₹2,811 Cr+11.3%
FY2023₹2,526 Cr+14.0%
FY2022₹2,215 Cr+16.0%
FY2021₹1,909 Cr
Revenue Trend (₹ Cr)

View Jyothy Laboratories Limited's full 10-year revenue trend with CAGR analysis →

Jyothy Lab Profitability

Profitability was essentially flat for Jyothy Laboratories Limited, with net profit of ₹370 Cr in FY2025 versus FY2024.

The net margin remained stable around 12.8%, consistent with the prior year.

FY2025 diluted EPS of ₹10.09 was up from the ₹10.06 reported in FY2024.

Net Profit Trend (₹ Cr)

Is Jyothy Lab Undervalued

Per the P/E Ratio model, Jyothy Laboratories Limited has an estimated intrinsic value of ₹354 (77.1% upside).

Jyothy Laboratories Limited shares are currently trading at ₹199.98.

Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.

Valuation Models
ModelEst. Fair Valuevs. Current Price
P/E Ratio₹35477.1% upside to fair value
EPS GrowthUpgradeUpgrade
DCFUpgradeUpgrade

See all valuation models for Jyothy Laboratories Limited with detailed assumptions →

Jyothy Lab Shareholding Pattern

A stable promoter holding of 62.9% over 4 quarters suggests the management group is comfortable with its position.

Foreign institutions moved their stake down to 12.3% from 12.7% over the past year.

DII ownership is at 14.6%, down from the 16.0% recorded a year ago.

Shareholding Pattern (Last 4 Quarters)
QuarterPromoterFIIDIIPublic
Mar 202662.9%12.3%14.6%10.1%
Dec 202562.9%12.8%15.1%9.2%
Sep 202562.9%12.1%16.1%8.9%
Jun 202562.9%12.7%16.0%8.5%

Track quarterly shareholding changes for Jyothy Laboratories Limited →

Jyothy Lab Balance Sheet

Proportional view as of 3 Jun 2026. Hover blocks for details.

Assets

Liabilities & Equity

Total assets stood at ₹26.91B at the end of FY2025, up 12.1% from ₹24.01B a year earlier.

Intangibles & Goodwill is the largest block at 29.5%, followed by Cash & ST Investments at 19.8% and Other Assets at 16.6%.

Equity makes up 76.2% of liabilities and equity, with debt at 2.3% and operating liabilities at 21.6%. Over the year, debt is up 21.2% and equity is up 13.2%.

Balance sheet composition — FY 2025

Assets (values in Indian Rupees, with M = millions, B = billions)
CategoryValue
Cash & ST Investments 5.34B
Receivables 2.74B
Inventories 3.28B
Property, Plant & Equipment 3.15B
Intangibles & Goodwill 7.93B
Other Assets 4.47B
Liabilities and equity (values in Indian Rupees, with M = millions, B = billions)
CategoryValue
Equity 20.50B
Short-term Debt 247.60M
Long-term Debt 365.20M
Trade Payables 2.90B
Other Liabilities 2.90B

View full balance sheet (multi-year) →

Jyothy Lab at a Glance

Bringing the key threads together for Jyothy Laboratories Limited (JYOTHYLAB) as a personal care investment opportunity.

Revenue of ₹2,903 Cr in FY2025, up 3.3% year-over-year.

Long-term revenue has been compounding at 6.7% annually over 10 years.

The company is profitable, with a net margin of 12.8% and net income of ₹370 Cr.

The P/E Ratio model implies 77.1% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.

Unlock Full Analysis

Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Jyothy Laboratories Limited.

Related Stocks